Quiroz 2016.

Study characteristics
Methods	Double‐blind, randomised, placebo‐controlled, multi‐centre trial
Participants	Diagnosis: DSM‐IV‐TR major depressive disorder N: 333 Age: basimglurant 0.5 mg group M = 45.8 (SD = 10.8); basimglurant 1.5 mg group M = 47.0 (SD = 17.1); placebo group M = 47.1 (SD = 11.3) Sex: basimglurant 0.5bmg group 62.5% female; basimglurant 1.5bmg group 69.4% female; placebo group 63.3% female Baseline depression severity: basimglurant 0.5bmg group MADRS = 31.1 (SD = 3.9); basimglurant 1.5bmg group MADRS = 31.3 (SD = 4.6); placebo group MADRS = 31.1 (SD = 4.7)
Interventions	Patients were randomised to receive 6‐weeks of treatment with 0.5 mg basimglurant, 1.5 mg basimglurant, or placebo, orally once daily. This was adjunctive to their ongoing antidepressant medication therapy.
Outcomes	MADRS QIDS‐SR16 CGI‐S SDS (items 2‐3) Q‐LES‐Q‐SF PGI‐I Response (≥50% reduction in MADRS total score from baseline) Remission (MADRS total score ≤10)
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Patients randomised in a 1:1:1 ratio.
Allocation concealment (selection bias)	Low risk	Patients randomised in a 1:1:1 ratio.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Stated but not tested.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Stated but not tested.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Diagram of patient numbers and reasons for withdrawal included in figure 1 (page 678).
Selective reporting (reporting bias)	Low risk	Trial registration available online (NCT01437657). All outcomes reported.
Other bias	High risk	Potential funding bias. Quote: "This study was sponsored by F. Hoffmann‐La Roche Ltd."